Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer

Cancer Letters

Volumn 320, Issue 2, 2012, Pages 158-170

  Shanmugam, Muthu K ^a   Nguyen, An H ^a   Kumar, Alan P ^a,b,c   Tan, Benny K H ^a   Sethi, Gautam ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Apoptosis; Cancer; Metastasis; Proliferation; Triterpenoids

Indexed keywords

11 KETO BETA BOSWELLIC ACID; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; ACETYL 11 OXO BETA BOSWELLIC ACID; AMOORANIN; ASIATIC ACID; AVICIN; BARDOXOLONE; BARDOXOLONE METHYL; BETA ESCIN; BETULIC ACID; BORTEZOMIB; BOSWELLIC ACID; CELASTROL; CENTELLA ASIATICA EXTRACT; DOXORUBICIN; ESCIN; FLUOROURACIL; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; LUPEOL; NVX 207; OLEANOLIC ACID; PACLITAXEL; PENTACYCLIC TRITERPENE; PRISTIMERIN; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; URSOLIC ACID;

ADJUVANT ARTHRITIS; ALZHEIMER DISEASE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTHRITIS; ASTHMA; BREAST CANCER; BREAST TUMOR; CANCER INHIBITION; CANCER PREVENTION; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE ARREST; COLON CANCER; COLON TUMOR; COLORECTAL CANCER; CROHN DISEASE; DISTANT METASTASIS; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TUMOR LEVEL; EHRLICH ASCITES TUMOR; GLIOMA; HEAD AND NECK CANCER; HUMAN; ILEITIS; INFLAMMATION; LEUKEMIA; LEWIS CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG METASTASIS; LUNG TUBERCULOSIS; MELANOMA; METASTASIS INHIBITION; NEOPLASM; NONHUMAN; OSTEOARTHRITIS; OTITIS; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; RHEUMATOID ARTHRITIS; SHORT SURVEY; SKIN CANCER; SKIN TUMOR; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THYMOMA; TOXIC HEPATITIS; TUMOR GROWTH; ULCERATIVE COLITIS;

EID: 84862779635     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.037     Document Type: Review

References (222)

1. Balunas M.J., Kinghorn A.D. Drug discovery from medicinal plants. Life Sci. 2005, 78:431-441.
2. Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 2006, 71:1397-1421.
3. Aggarwal B.B., Vijayalekshmi R.V., Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2009, 15:425-430.
4. Sethi G., Tergaonkar V. Potential pharmacological control of the NF-kappaB pathway. Trends Pharmacol. Sci. 2009, 30:313-321.
5. Grivennikov S.I., Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann. Rheum. Dis. 2011, 70(Suppl. 1):i104-i108.
6. Kannaiyan R., Shanmugam M.K., Sethi G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 2011, 303:9-20.
7. Aggarwal B.B., Kunnumakkara A.B., Harikumar K.B., Tharakan S.T., Sung B., Anand P. Potential of spice-derived phytochemicals for cancer prevention. Planta Med. 2008, 74:1560-1569.
8. Gautam R., Jachak S.M. Recent developments in anti-inflammatory natural products. Med. Res. Rev. 2009, 29:767-820.
9. Shanmugam M.K., Kannaiyan R., Sethi G. Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr. Cancer 2011, 63:161-173.
10. Connolly J.D., Hill R.A. Triterpenoids. Nat. Prod. Rep. 2010, 27:79-132.
11. Liby K.T., Yore M.M., Sporn M.B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat. Rev. Cancer 2007, 7:357-369.
12. Estrada A.C., Syrovets T., Pitterle K., Lunov O., Buchele B., Schimana-Pfeifer J., Schmidt T., Morad S.A., Simmet T. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells. Mol. Pharmacol. 2010, 77:378-387.
13. Petronelli A., Pannitteri G., Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs 2009, 20:880-892.
14. Deeb D., Gao X., Dulchavsky S.A., Gautam S.C. CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells. J. Exp. Ther. Oncol. 2008, 7:31-39.
15. Liby K., Royce D.B., Williams C.R., Risingsong R., Yore M.M., Honda T., Gribble G.W., Dmitrovsky E., Sporn T.A., Sporn M.B. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 2007, 67:2414-2419.
16. Sporn M.B., Liby K.T., Yore M.M., Fu L., Lopchuk J.M., Gribble G.W. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J. Nat. Prod. 2011, 74:537-545.
17. James J.T., Dubery I.A. Pentacyclic triterpenoids from the medicinal herb, Centella asiatica (L.) Urban. Molecules 2009, 14:3922-3941.
18. Tang X.L., Yang X.Y., Jung H.J., Kim S.Y., Jung S.Y., Choi D.Y., Park W.C., Park H. Asiatic acid induces colon cancer cell growth inhibition and apoptosis through mitochondrial death cascade. Biol. Pharm. Bull. 2009, 32:1399-1405.
19. Hsu Y.L., Kuo P.L., Lin L.T., Lin C.C. Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells. J. Pharmacol. Exp. Ther. 2005, 313:333-344.
20. Gurfinkel D.M., Chow S., Hurren R., Gronda M., Henderson C., Berube C., Hedley D.W., Schimmer A.D. Disruption of the endoplasmic reticulum and increases in cytoplasmic calcium are early events in cell death induced by the natural triterpenoid Asiatic acid. Apoptosis 2006, 11:1463-1471.
21. Park B.C., Bosire K.O., Lee E.S., Lee Y.S., Kim J.A. Asiatic acid induces apoptosis in SK-MEL-2 human melanoma cells. Cancer Lett. 2005, 218:81-90.
22. 2+ release and enhanced expression of p53 in HepG2 human hepatoma cells. Cancer Lett. 2002, 186:83-91.
23. Cho C.W., Choi D.S., Cardone M.H., Kim C.W., Sinskey A.J., Rha C. Glioblastoma cell death induced by Asiatic acid. Cell Biol. Toxicol. 2006, 22:393-408.
24. Bunpo P., Kataoka K., Arimochi H., Nakayama H., Kuwahara T., Bando Y., Izumi K., Vinitketkumnuen U., Ohnishi Y. Inhibitory effects of Centella asiatica on azoxymethane-induced aberrant crypt focus formation and carcinogenesis in the intestines of F344 rats. Food Chem. Toxicol. 2004, 42:1987-1997.
25. Bunpo P., Kataoka K., Arimochi H., Nakayama H., Kuwahara T., Vinitketkumnuen U., Ohnishi Y. Inhibitory effects of Asiatic acid and CPT-11 on growth of HT-29 cells. J. Med. Invest. 2005, 52:65-73.
26. Aguirre M.C., Delporte C., Backhouse N., Erazo S., Letelier M.E., Cassels B.K., Silva X., Alegria S., Negrete R. Topical anti-inflammatory activity of 2alpha-hydroxy pentacyclic triterpene acids from the leaves of Ugni molinae. Bioorg. Med. Chem. 2006, 14:5673-5677.
27. Park B.C., Paek S.H., Lee Y.S., Kim S.J., Lee E.S., Choi H.G., Yong C.S., Kim J.A. Inhibitory effects of asiatic acid on 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol 13-acetate-induced tumor promotion in mice. Biol. Pharm. Bull. 2007, 30:176-179.
28. Haridas V., Higuchi M., Jayatilake G.S., Bailey D., Mujoo K., Blake M.E., Arntzen C.J., Gutterman J.U. Avicins: triterpenoid saponins from Acacia victoriae (Bentham) induce apoptosis by mitochondrial perturbation. Proc. Natl. Acad. Sci. USA 2001, 98:5821-5826.
29. Mujoo K., Haridas V., Hoffmann J.J., Wachter G.A., Hutter L.K., Lu Y., Blake M.E., Jayatilake G.S., Bailey D., Mills G.B., Gutterman J.U. Triterpenoid saponins from Acacia victoriae (Bentham) decrease tumor cell proliferation and induce apoptosis. Cancer Res. 2001, 61:5486-5490.
30. Jayatilake G.S., Freeberg D.R., Liu Z., Richheimer S.L., Blake Nieto M.E., Bailey D.T., Haridas V., Gutterman J.U. Isolation and structures of avicins D and G: in vitro tumor-inhibitory saponins derived from Acacia victoriae. J. Nat. Prod. 2003, 66:779-783.
31. Haridas V., Arntzen C.J., Gutterman J.U. Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), inhibit activation of nuclear factor-kappaB by inhibiting both its nuclear localization and ability to bind DNA. Proc. Natl. Acad. Sci. USA 2001, 98:11557-11562.
32. Haridas V., Hanausek M., Nishimura G., Soehnge H., Gaikwad A., Narog M., Spears E., Zoltaszek R., Walaszek Z., Gutterman J.U. Triterpenoid electrophiles (avicins) activate the innate stress response by redox regulation of a gene battery. J. Clin. Invest. 2004, 113:65-73.
33. Hanausek M., Ganesh P., Walaszek Z., Arntzen C.J., Slaga T.J., Gutterman J.U. Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), suppress H-ras mutations and aneuploidy in a murine skin carcinogenesis model. Proc. Natl. Acad. Sci. USA 2001, 98:11551-11556.
34. Haridas V., Kim S.O., Nishimura G., Hausladen A., Stamler J.S., Gutterman J.U. Avicinylation (thioesterification): a protein modification that can regulate the response to oxidative and nitrosative stress. Proc. Natl. Acad. Sci. USA 2005, 102:10088-10093.
35. Gaikwad A., Poblenz A., Haridas V., Zhang C., Duvic M., Gutterman J. Triterpenoid electrophiles (avicins) suppress heat shock protein-70 and x-linked inhibitor of apoptosis proteins in malignant cells by activation of ubiquitin machinery: implications for proapoptotic activity. Clin. Cancer Res. 2005, 11:1953-1962.
36. Xu Z.X., Liang J., Haridas V., Gaikwad A., Connolly F.P., Mills G.B., Gutterman J.U. A plant triterpenoid, avicin D, induces autophagy by activation of AMP-activated protein kinase. Cell Death Differ. 2007, 14:1948-1957.
37. Xu Z.X., Ding T., Haridas V., Connolly F., Gutterman J.U. Avicin D, a plant triterpenoid, induces cell apoptosis by recruitment of Fas and downstream signaling molecules into lipid rafts. PLoS ONE 2009, 4:e8532.
38. Wang H., Haridas V., Gutterman J.U., Xu Z.X. Natural triterpenoid avicins selectively induce tumor cell death. Commun. Integr. Biol. 2010, 3:205-208.
39. Haridas V., Nishimura G., Xu Z.X., Connolly F., Hanausek M., Walaszek Z., Zoltaszek R., Gutterman J.U. Avicin D: a protein reactive plant isoprenoid dephosphorylates Stat 3 by regulating both kinase and phosphatase activities. PLoS ONE 2009, 4:e5578.
40. Zhang C., Li B., Gaikwad A.S., Haridas V., Xu Z., Gutterman J.U., Duvic M. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. J. Invest. Dermatol. 2008, 128:2728-2735.
41. Haridas V., Li X., Mizumachi T., Higuchi M., Lemeshko V.V., Colombini M., Gutterman J.U. Avicins, a novel plant-derived metabolite lowers energy metabolism in tumor cells by targeting the outer mitochondrial membrane. Mitochondrion 2007, 7:234-240.
42. Lemeshko V.V., Haridas V., Quijano Perez J.C., Gutterman J.U. Avicins, natural anticancer saponins, permeabilize mitochondrial membranes. Arch. Biochem. Biophys. 2006, 454:114-122.
43. Pisha E., Chai H., Lee I.S., Chagwedera T.E., Farnsworth N.R., Cordell G.A., Beecher C.W., Fong H.H., Kinghorn A.D., Brown D.M., et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat. Med. 1995, 1:1046-1051.
44. Zuco V., Supino R., Righetti S.C., Cleris L., Marchesi E., Gambacorti-Passerini C., Formelli F. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett. 2002, 175:17-25.
45. Fulda S., Friesen C., Los M., Scaffidi C., Mier W., Benedict M., Nunez G., Krammer P.H., Peter M.E., Debatin K.M. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res. 1997, 57:4956-4964.
46. Jeremias I., Steiner H.H., Benner A., Debatin K.M., Herold-Mende C. Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells. Acta Neurochir. (Wien) 2004, 146:721-729.
47. Tan Y., Yu R., Pezzuto J.M. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin. Cancer Res. 2003, 9:2866-2875.
48. Takada Y., Aggarwal B.B. Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J. Immunol. 2003, 171:3278-3286.
49. Chintharlapalli S., Papineni S., Ramaiah S.K., Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res. 2007, 67:2816-2823.
50. Pandey M.K., Sung B., Aggarwal B.B. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int. J. Cancer. J. Int. du Cancer 2010, 127:282-292.
51. Ji Z.N., Ye W.C., Liu G.G., Hsiao W.L. 23-Hydroxybetulinic acid-mediated apoptosis is accompanied by decreases in bcl-2 expression and telomerase activity in HL-60 Cells. Life Sci. 2002, 72:1-9.
52. Fulda S., Scaffidi C., Susin S.A., Krammer P.H., Kroemer G., Peter M.E., Debatin K.M. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J. Biol. Chem. 1998, 273:33942-33948.
53. Fulda S., Kroemer G. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov. Today 2009, 14:885-890.
54. Fulda S., Debatin K.M. Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Med. Pediatr. Oncol. 2000, 35:616-618.
55. Salti G.I., Kichina J.V., Das Gupta T.K., Uddin S., Bratescu L., Pezzuto J.M., Mehta R.G., Constantinou A.I. Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent. Melanoma Res. 2001, 11:99-104.
56. Meng R.D., El-Deiry W.S. P53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp. Cell Res. 2001, 262:154-169.
57. Selzer E., Pimentel E., Wacheck V., Schlegel W., Pehamberger H., Jansen B., Kodym R. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J. Invest. Dermatol. 2000, 114:935-940.
58. Wick W., Grimmel C., Wagenknecht B., Dichgans J., Weller M. Betulinic acid-induced apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J. Pharmacol. Exp. Ther. 1999, 289:1306-1312.
59. Fulda S., Jeremias I., Debatin K.M. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene 2004, 23:7611-7620.
60. Fulda S., Debatin K.M. Sensitization for anticancer drug-induced apoptosis by betulinic acid. Neoplasia 2005, 7:162-170.
61. Honda T., Liby K.T., Su X., Sundararajan C., Honda Y., Suh N., Risingsong R., Williams C.R., Royce D.B., Sporn M.B., Gribble G.W. Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. Bioorg. Med. Chem. Lett. 2006, 16:6306-6309.
62. Fukuda Y., Sakai K., Matsunaga S., Tokuda H., Tanaka R. Cancer chemopreventive effect of orally administrated lupane-type triterpenoid on ultraviolet light B induced photocarcinogenesis of hairless mouse. Cancer Lett. 2006, 240:94-101.
63. Willmann M., Wacheck V., Buckley J., Nagy K., Thalhammer J., Paschke R., Triche T., Jansen B., Selzer E. Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound. Eur. J. Clin. Invest. 2009, 39:384-394.
64. Aggarwal B.B., Ichikawa H., Garodia P., Weerasinghe P., Sethi G., Bhatt I.D., Pandey M.K., Shishodia S., Nair M.G. From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin. Ther. Targets 2006, 10:87-118.
65. Sailer E.R., Subramanian L.R., Rall B., Hoernlein R.F., Ammon H.P., Safayhi H. Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br. J. Pharmacol. 1996, 117:615-618.
66. Liu J.J., Nilsson A., Oredsson S., Badmaev V., Zhao W.Z., Duan R.D. Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis 2002, 23:2087-2093.
67. Kunnumakkara A.B., Nair A.S., Sung B., Pandey M.K., Aggarwal B.B. Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol. Cancer Res.: MCR 2009, 7:118-128.
68. Yadav V.R., Prasad S., Sung B., Kannappan R., Aggarwal B.B. Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel) 2010, 2:2428-2466.
69. Anthoni C., Laukoetter M.G., Rijcken E., Vowinkel T., Mennigen R., Muller S., Senninger N., Russell J., Jauch J., Bergmann J., Granger D.N., Krieglstein C.F. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G1131-G1137.
70. Kiela P.R., Midura A.J., Kuscuoglu N., Jolad S.D., Solyom A.M., Besselsen D.G., Timmermann B.N., Ghishan F.K. Effects of Boswellia serrata in mouse models of chemically induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G798-G808.
71. Takada Y., Ichikawa H., Badmaev V., Aggarwal B.B. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. J. Immunol. 2006, 176:3127-3140.
72. Syrovets T., Buchele B., Krauss C., Laumonnier Y., Simmet T. Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-alpha induction in monocytes by direct interaction with IkappaB kinases. J. Immunol. 2005, 174:498-506.
73. Agrawal S.S., Saraswati S., Mathur R., Pandey M. Antitumor properties of Boswellic acid against Ehrlich ascites cells bearing mouse. Food Chem. Toxicol.: Int. J. Publish. Br. Indust. Biol. Res. Assoc. 2011, 49:1924-1934.
74. Khan S., Chib R., Shah B.A., Wani Z.A., Dhar N., Mondhe D.M., Lattoo S., Jain S.K., Taneja S.C., Singh J. A cyano analogue of boswellic acid induces crosstalk between p53/PUMA/Bax and telomerase that stages the human papillomavirus type 18 positive HeLa cells to apoptotic death. Eur. J. Pharmacol. 2011, 660:241-248.
75. Chashoo G., Singh S.K., Sharma P.R., Mondhe D.M., Hamid A., Saxena A., Andotra S.S., Shah B.A., Qazi N.A., Taneja S.C., Saxena A.K. A propionyloxy derivative of 11-keto-beta-boswellic acid induces apoptosis in HL-60 cells mediated through topoisomerase I & II inhibition. Chem. Biol. Interact. 2011, 189:60-71.
76. Pang X., Yi Z., Zhang X., Sung B., Qu W., Lian X., Aggarwal B.B., Liu M. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res. 2009, 69:5893-5900.
77. Shah B.A., Kumar A., Gupta P., Sharma M., Sethi V.K., Saxena A.K., Singh J., Qazi G.N., Taneja S.C. Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids. Bioorg. Med. Chem. Lett. 2007, 17:6411-6416.
78. Liu J.J., Huang B., Hooi S.C. Acetyl-keto-beta-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells. Br. J. Pharmacol. 2006, 148:1099-1107.
79. Syrovets T., Buchele B., Gedig E., Slupsky J.R., Simmet T. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha. Mol. Pharmacol. 2000, 58:71-81.
80. Singh S., Khajuria A., Taneja S.C., Johri R.K., Singh J., Qazi G.N. Boswellic acids: a leukotriene inhibitor also effective through topical application in inflammatory disorders. Phytomed.: Int. J. Phytother. Phytopharmacol. 2008, 15:400-407.
81. Moussaieff A., Mechoulam R. Boswellia resin: from religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J. Pharm. Pharmacol. 2009, 61:1281-1293.
82. Wang H., Syrovets T., Kess D., Buchele B., Hainzl H., Lunov O., Weiss J.M., Scharffetter-Kochanek K., Simmet T. Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. J. Immunol. 2009, 183:4755-4763.
83. Sethi G., Ahn K.S., Pandey M.K., Aggarwal B.B. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007, 109:2727-2735.
84. He M.F., Liu L., Ge W., Shaw P.C., Jiang R., Wu L.W., But P.P. Antiangiogenic activity of Tripterygium wilfordii and its terpenoids. J. Ethnopharmacol. 2009, 121:61-68.
85. Salminen A., Lehtonen M., Paimela T., Kaarniranta K. Celastrol: molecular targets of Thunder God Vine. Biochem. Biophys. Res. Commun. 2010, 394:439-442.
86. Wu X., Lee V.C., Chevalier E., Hwang S.T. Chemokine receptors as targets for cancer therapy. Curr. Pharm. Des. 2009, 15:742-757.
87. Pang X., Yi Z., Zhang J., Lu B., Sung B., Qu W., Aggarwal B.B., Liu M. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 2010, 70:1951-1959.
88. Sung B., Park B., Yadav V.R., Aggarwal B.B. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J. Biol. Chem. 2010, 285:11498-11507.
89. Zhang D., Xu L., Cao F., Wei T., Yang C., Uzan G., Peng B. Celastrol regulates multiple nuclear transcription factors belonging to HSP90's clients in a dose- and cell type-dependent way. Cell Stress Chaperones 2010, 15:939-946.
90. Zhu H., Ding W.J., Wu R., Weng Q.J., Lou J.S., Jin R.J., Lu W., Yang B., He Q.J. Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest. 2010, 28:23-32.
91. Zhu H., Liu X.W., Ding W.J., Xu D.Q., Zhao Y.C., Lu W., He Q.J., Yang B. Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. Cancer Lett. 2010, 297:155-164.
92. Kannaiyan R., Manu K.A., Chen L., Li F., Rajendran P., Subramaniam A., Lam P., Kumar A.P., Sethi G. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis: Int. J. Program. Cell Death 2011, 16:1028-1041.
93. Yang H., Chen D., Cui Q.C., Yuan X., Dou Q.P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine", is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006, 66:4758-4765.
94. Nagase M., Oto J., Sugiyama S., Yube K., Takaishi Y., Sakato N. Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci. Biotechnol. Biochem. 2003, 67:1883-1887.
95. Kannaiyan R., Hay H.S., Rajendran P., Li F., Shanmugam M.K., Vali S., Abbasi T., Kapoor S., Sharma A., Kumar A.P., Chng W.J., Sethi G. Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells. Br. J. Pharmacol. 2011, 164:1506-1521.
96. Huang Y., Zhou Y., Fan Y., Zhou D. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett. 2008, 264:101-106.
97. Lu Z., Jin Y., Qiu L., Lai Y., Pan J. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett. 2010, 290:182-191.
98. Westerheide S.D., Bosman J.D., Mbadugha B.N., Kawahara T.L., Matsumoto G., Kim S., Gu W., Devlin J.P., Silverman R.B., Morimoto R.I. Celastrols as inducers of the heat shock response and cytoprotection. J. Biol. Chem. 2004, 279:56053-56060.
99. Zhang T., Hamza A., Cao X., Wang B., Yu S., Zhan C.G., Sun D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 2008, 7:162-170.
100. Kim Y., Kim K., Lee H., Han S., Lee Y.S., Choe J., Kim Y.M., Hahn J.H., Ro J.Y., Jeoung D. Celastrol binds to ERK and inhibits FcepsilonRI signaling to exert an anti-allergic effect. Eur. J. Pharmacol. 2009, 612:131-142.
101. Hieronymus H., Lamb J., Ross K.N., Peng X.P., Clement C., Rodina A., Nieto M., Du J., Stegmaier K., Raj S.M., Maloney K.N., Clardy J., Hahn W.C., Chiosis G., Golub T.R. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006, 10:321-330.
102. Abbas S., Bhoumik A., Dahl R., Vasile S., Krajewski S., Cosford N.D., Ronai Z.A. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin. Cancer Res. 2007, 13:6769-6778.
103. Raja S.M., Clubb R.J., Ortega-Cava C., Williams S.H., Bailey T.A., Duan L., Zhao X., Reddi A.L., Nyong A.M., Natarajan A., Band V., Band H. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol. Ther. 2011, 11:263-276.
104. Zhu H., Liu X.W., Cai T.Y., Cao J., Tu C.X., Lu W., He Q.J., Yang B. Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway. J. Pharmacol. Exp. Ther. 2010, 334:489-499.
105. Matsuda H., Li Y., Murakami T., Ninomiya K., Yamahara J., Yoshikawa M. Effects of escins Ia, Ib, IIa, and IIb from horse chestnut, the seeds of Aesculus hippocastanum L., on acute inflammation in animals. Biol. Pharm. Bull. 1997, 20:1092-1095.
106. Rothkopf M., Vogel G. New findings on the efficacy and mode of action of the horse chestnut saponin escin. Arzneimittelforschung 1976, 26:225-235.
107. Matsuda H., Murakami T., Li Y., Yamahara J., Yoshikawa M. Mode of action of escins Ia and IIa and E, Z-senegin II on glucose absorption in gastrointestinal tract. Bioorg. Med. Chem. 1998, 6:1019-1023.
108. Patlolla J.M., Raju J., Swamy M.V., Rao C.V. Beta-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21(waf1/cip1) in colon cancer cells. Mol. Cancer Ther. 2006, 5:1459-1466.
109. Harikumar K.B., Sung B., Pandey M.K., Guha S., Krishnan S., Aggarwal B.B. Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol. Pharmacol. 2010, 77:818-827.
110. Niu Y.P., Li L.D., Wu L.M. Beta-aescin: a potent natural inhibitor of proliferation and inducer of apoptosis in human chronic myeloid leukemia K562 cells in vitro. Leuk. Lymphoma 2008, 49:1384-1391.
111. Niu Y.P., Wu L.M., Jiang Y.L., Wang W.X., Li L.D. Beta-escin, a natural triterpenoid saponin from Chinese horse chestnut seeds, depresses HL-60 human leukaemia cell proliferation and induces apoptosis. J. Pharm. Pharmacol. 2008, 60:1213-1220.
112. D.Y. Shen, J.H. Kang, W. Song, W.Q. Zhang, W.G. Li, Y. Zhao, Q.X. Chen, Apoptosis of human cholangiocarcinoma cell lines induced by beta-escin through mitochondrial caspase-dependent pathway. Phytother. Res., 2011.
113. Zhou X.Y., Fu F.H., Li Z., Dong Q.J., He J., Wang C.H. Escin, a natural mixture of triterpene saponins, exhibits antitumor activity against hepatocellular carcinoma. Planta Med. 2009, 75:1580-1585.
114. Tan S.M., Li F., Rajendran P., Kumar A.P., Hui K.M., Sethi G. Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 2010, 334:285-293.
115. Ming Z.J., Hu Y., Qiu Y.H., Cao L., Zhang X.G. Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. Phytomedicine 2010, 17:575-580.
116. Hu X.M., Zhang Y., Zeng F.D. Effects of beta-aescin on apoptosis induced by transient focal cerebral ischemia in rats. Acta Pharmacol. Sinica 2004, 25:1267-1275.
117. Montopoli M., Froldi G., Comelli M.C., Prosdocimi M., Caparrotta L. Aescin protection of human vascular endothelial cells exposed to cobalt chloride mimicked hypoxia and inflammatory stimuli. Planta Med. 2007, 73:285-288.
118. D.B. Ji, B. Xu, J.T. Liu, F.X. Ran, J.R. Cui, Beta-escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells, Mol. Carcinog, 2011.
119. Wang X.H., Xu B., Liu J.T., Cui J.R. Effect of beta-escin sodium on endothelial cells proliferation, migration and apoptosis. Vascul. Pharmacol. 2008, 49:158-165.
120. Xin W., Zhang L., Sun F., Jiang N., Fan H., Wang T., Li Z., He J., Fu F. Escin exerts synergistic anti-inflammatory effects with low doses of glucocorticoids in vivo and in vitro. Phytomedicine 2011, 18:272-277.
121. Asl M.N., Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother. Res. 2008, 22:709-724.
122. Hibasami H., Iwase H., Yoshioka K., Takahashi H. Glycyrrhizin induces apoptosis in human stomach cancer KATO III and human promyelotic leukemia HL-60 cells. Int. J. Mol. Med. 2005, 16:233-236.
123. Rossi T., Castelli M., Zandomeneghi G., Ruberto A., Benassi L., Magnoni C., Santachiara S., Baggio G. Selectivity of action of glycyrrhizin derivatives on the growth of MCF-7 and HEP-2 cells. Anticancer Res. 2003, 23:3813-3818.
124. Rossi T., Benassi L., Magnoni C., Ruberto A.I., Coppi A., Baggio G. Effects of glycyrrhizin on UVB-irradiated melanoma cells. In Vivo 2005, 19:319-322.
125. G. Sharma, S. Kar, S. Palit, P.K. Das, 18beta-Glycyrrhetinic acid induces apoptosis through modulation of Akt/FOXO3a/Bim pathway in human breast cancer MCF-7 cells. J. Cell Physiol., 2011.
126. Lee C.S., Kim Y.J., Lee M.S., Han E.S., Lee S.J. 18beta-Glycyrrhetinic acid induces apoptotic cell death in SiHa cells and exhibits a synergistic effect against antibiotic anti-cancer drug toxicity. Life Sci. 2008, 83:481-489.
127. Satomi Y., Nishino H., Shibata S. Glycyrrhetinic acid and related compounds induce G1 arrest and apoptosis in human hepatocellular carcinoma HepG2. Anticancer Res. 2005, 25:4043-4047.
128. Chintharlapalli S., Papineni S., Jutooru I., McAlees A., Safe S. Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor gamma agonists in colon cancer cells. Mol. Cancer Ther. 2007, 6:1588-1598.
129. Hsiang C.Y., Lai I.L., Chao D.C., Ho T.Y. Differential regulation of activator protein 1 activity by glycyrrhizin. Life Sci. 2002, 70:1643-1656.
130. Niwa K., Lian Z., Onogi K., Yun W., Tang L., Mori H., Tamaya T. Preventive effects of glycyrrhizin on estrogen-related endometrial carcinogenesis in mice. Oncol. Rep. 2007, 17:617-622.
131. Cherng J.M., Tsai K.D., Yu Y.W., Lin J.C. Molecular mechanisms underlying chemopreventive activities of glycyrrhizic acid against UVB-radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis. Radiat. Res. 2011, 176:177-186.
132. Raphael T.J., Kuttan G. Effect of naturally occurring triterpenoids ursolic acid and glycyrrhizic acid on the cell-mediated immune responses of metastatic tumor-bearing animals. Immunopharmacol. Immunotoxicol. 2008, 30:243-255.
133. Saleem M. Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett. 2009, 285:109-115.
134. Saleem M., Afaq F., Adhami V.M., Mukhtar H. Lupeol modulates NF-kappaB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice. Oncogene 2004, 23:5203-5214.
135. Lee T.K., Poon R.T., Wo J.Y., Ma S., Guan X.Y., Myers J.N., Altevogt P., Yuen A.P. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res. 2007, 67:8800-8809.
136. Fernandez M.A., de las Heras B., Garcia M.D., Saenz M.T., Villar A. New insights into the mechanism of action of the anti-inflammatory triterpene lupeol. J. Pharm Pharmacol. 2001, 53:1533-1539.
137. Prasad S., Madan E., Nigam N., Roy P., George J., Shukla Y. Induction of apoptosis by lupeol in human epidermoid carcinoma A431 cells through regulation of mitochondrial, Akt/PKB and NFkappaB signaling pathways. Cancer Biol. Ther. 2009, 8:1632-1639.
138. Siddique H.R., Saleem M. Beneficial health effects of lupeol triterpene: a review of preclinical studies. Life Sci. 2011, 88:285-293.
139. Siddique H.R., Mishra S.K., Karnes R.J., Saleem M. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin. Cancer Res. 2011, 17:5379-5391.
140. Saleem M., Maddodi N., Abu Zaid M., Khan N., Bin Hafeez B., Asim M., Suh Y., Yun J.M., Setaluri V., Mukhtar H. Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin. Cancer Res. 2008, 14:2119-2127.
141. Saleem M., Murtaza I., Tarapore R.S., Suh Y., Adhami V.M., Johnson J.J., Siddiqui I.A., Khan N., Asim M., Hafeez B.B., Shekhani M.T., Li B., Mukhtar H. Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling. Carcinogenesis 2009, 30:808-817.
142. Saleem M., Murtaza I., Witkowsky O., Kohl A.M., Maddodi N. Lupeol triterpene, a novel diet-based microtubule targeting agent: disrupts survivin/cFLIP activation in prostate cancer cells. Biochem. Biophys. Res. Commun. 2009, 388:576-582.
143. Tarapore R.S., Siddiqui I.A., Saleem M., Adhami V.M., Spiegelman V.S., Mukhtar H. Specific targeting of Wnt/beta-catenin signaling in human melanoma cells by a dietary triterpene lupeol. Carcinogenesis 2010, 31:1844-1853.
144. Murtaza I., Saleem M., Adhami V.M., Hafeez B.B., Mukhtar H. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res. 2009, 69:1156-1165.
145. Khan N., Afaq F., Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid. Redox Signal. 2008, 10:475-510.
146. Lee T.K., Castilho A., Cheung V.C., Tang K.H., Ma S., Ng I.O. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 2011, 53:160-170.
147. Oguro T., Liu J., Klaassen C.D., Yoshida T. Inhibitory effect of oleanolic acid on 12-O-tetradecanoylphorbol-13-acetate-induced gene expression in mouse skin. Toxicol. Sci. 1998, 45:88-93.
148. Zhang P., Li H., Chen D., Ni J., Kang Y., Wang S. Oleanolic acid induces apoptosis in human leukemia cells through caspase activation and poly(ADP-ribose) polymerase cleavage. Acta Biochim. Biophys. Sinica (Shanghai) 2007, 39:803-809.
149. Fukumura M., Ando H., Hirai Y., Toriizuka K., Ida Y., Kuchino Y. Achyranthoside H methyl ester, a novel oleanolic acid saponin derivative from Achyranthes fauriei roots, induces apoptosis in human breast cancer MCF-7 and MDA-MB-453 cells via a caspase activation pathway. J. Nat. Med. 2009, 63:181-188.
150. Juan M.E., Planas J.M., Ruiz-Gutierrez V., Daniel H., Wenzel U. Antiproliferative and apoptosis-inducing effects of maslinic and oleanolic acids, two pentacyclic triterpenes from olives, on HT-29 colon cancer cells. Br. J. Nutr. 2008, 100:36-43.
151. Janakiram N.B., Indranie C., Malisetty S.V., Jagan P., Steele V.E., Rao C.V. Chemoprevention of colon carcinogenesis by oleanolic acid and its analog in male F344 rats and modulation of COX-2 and apoptosis in human colon HT-29 cancer cells. Pharm Res. 2008, 25:2151-2157.
152. Jung M.J., Yoo Y.C., Lee K.B., Kim J.B., Song K.S. Isolation of epi-oleanolic acid from Korean mistletoe and its apoptosis-lnducing activity in tumor cells. Arch Pharm Res. 2004, 27:840-844.
153. Bishayee A., Ahmed S., Brankov N., Perloff M. Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front Biosci. 2011, 16:980-996.
154. Chu R., Zhao X., Griffin C., Staub R.E., Shoemaker M., Climent J., Leitman D., Cohen I., Shtivelman E., Fong S. Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acid. Int. J. Cancer 2010, 127:1209-1219.
155. Deeb D., Gao X., Jiang H., Janic B., Arbab A.S., Rojanasakul Y., Dulchavsky S.A., Gautam S.C. Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism. Biochem. Pharmacol. 2010, 79:350-360.
156. Yan S.L., Huang C.Y., Wu S.T., Yin M.C. Oleanolic acid and ursolic acid induce apoptosis in four human liver cancer cell lines. Toxicol. In Vitro 2010, 24:842-848.
157. Konopleva M., Tsao T., Estrov Z., Lee R.M., Wang R.Y., Jackson C.E., McQueen T., Monaco G., Munsell M., Belmont J., Kantarjian H., Sporn M.B., Andreeff M. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res. 2004, 64:7927-7935.
158. Ovesna Z., Vachalkova A., Horvathova K., Tothova D. Pentacyclic triterpenoic acids: new chemoprotective compounds. Minireview. Neoplasma 2004, 51:327-333.
159. Zou W., Liu X., Yue P., Zhou Z., Sporn M.B., Lotan R., Khuri F.R., Sun S.Y. C-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 2004, 64:7570-7578.
160. Dinkova-Kostova A.T., Liby K.T., Stephenson K.K., Holtzclaw W.D., Gao X., Suh N., Williams C., Risingsong R., Honda T., Gribble G.W., Sporn M.B., Talalay P. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc. Natl. Acad. Sci. USA 2005, 102:4584-4589.
161. Eggler A.L., Gay K.A., Mesecar A.D. Molecular mechanisms of natural products in chemoprevention: induction of cytoprotective enzymes by Nrf2. Mol. Nutr. Food Res. 2008, 52(Suppl. 1):S84-S94.
162. Place A.E., Suh N., Williams C.R., Risingsong R., Honda T., Honda Y., Gribble G.W., Leesnitzer L.M., Stimmel J.B., Willson T.M., Rosen E., Sporn M.B. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin. Cancer Res. 2003, 9:2798-2806.
163. Shishodia S., Sethi G., Konopleva M., Andreeff M., Aggarwal B.B. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin. Cancer Res. 2006, 12:1828-1838.
164. Ahmad R., Raina D., Meyer C., Kharbanda S., Kufe D. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J. Biol. Chem. 2006, 281:35764-35769.
165. Ahmad R., Raina D., Meyer C., Kufe D. Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)→signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res. 2008, 68:2920-2926.
166. Yore M.M., Liby K.T., Honda T., Gribble G.W., Sporn M.B. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol. Cancer Ther. 2006, 5:3232-3239.
167. Sohn K.H., Lee H.Y., Chung H.Y., Young H.S., Yi S.Y., Kim K.W. Anti-angiogenic activity of triterpene acids. Cancer Lett. 1995, 94:213-218.
168. Sogno I., Vannini N., Lorusso G., Cammarota R., Noonan D.M., Generoso L., Sporn M.B., Albini A. Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids. Recent Results Cancer Res. 2009, 181:209-212.
169. Liu J. Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol. 1995, 49:57-68.
170. He X., Liu R.H. Cranberry phytochemicals: isolation, structure elucidation, and their antiproliferative and antioxidant activities. J. Agric. Food Chem. 2006, 54:7069-7074.
171. Kim D.K., Baek J.H., Kang C.M., Yoo M.A., Sung J.W., Chung H.Y., Kim N.D., Choi Y.H., Lee S.H., Kim K.W. Apoptotic activity of ursolic acid may correlate with the inhibition of initiation of DNA replication. Int. J. Cancer 2000, 87:629-636.
172. 2+ release mediates ursolic acid-induced apoptosis in human leukemic HL-60 cells. Int. J. Cancer 1997, 73:725-728.
173. Liu X.S., Jiang J. Induction of apoptosis and regulation of the MAPK pathway by ursolic acid in human leukemia K562 cells. Planta Med. 2007, 73:1192-1194.
174. Achiwa Y., Hasegawa K., Udagawa Y. Molecular mechanism of ursolic acid induced apoptosis in poorly differentiated endometrial cancer HEC108 cells. Oncol. Rep. 2005, 14:507-512.
175. Achiwa Y., Hasegawa K., Komiya T., Udagawa Y. Ursolic acid induces Bax-dependent apoptosis through the caspase-3 pathway in endometrial cancer SNG-II cells. Oncol. Rep. 2005, 13:51-57.
176. Harmand P.O., Duval R., Delage C., Simon A. Ursolic acid induces apoptosis through mitochondrial intrinsic pathway and caspase-3 activation in M4Beu melanoma cells. Int. J. Cancer 2005, 114:1-11.
177. Hsu Y.L., Kuo P.L., Lin C.C. Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci. 2004, 75:2303-2316.
178. Kassi E., Papoutsi Z., Pratsinis H., Aligiannis N., Manoussakis M., Moutsatsou P. Ursolic acid, a naturally occurring triterpenoid, demonstrates anticancer activity on human prostate cancer cells. J. Cancer Res. Clin. Oncol. 2007, 133:493-500.
179. Harmand P.O., Duval R., Liagre B., Jayat-Vignoles C., Beneytout J.L., Delage C., Simon A. Ursolic acid induces apoptosis through caspase-3 activation and cell cycle arrest in HaCat cells. Int. J. Oncol. 2003, 23:105-112.
180. Lauthier F., Taillet L., Trouillas P., Delage C., Simon A. Ursolic acid triggers calcium-dependent apoptosis in human Daudi cells. Anticancer Drugs 2000, 11:737-745.
181. Choi Y.H., Baek J.H., Yoo M.A., Chung H.Y., Kim N.D., Kim K.W. Induction of apoptosis by ursolic acid through activation of caspases and down-regulation of c-IAPs in human prostate epithelial cells. Int. J. Oncol. 2000, 17:565-571.
182. Hollosy F., Idei M., Csorba G., Szabo E., Bokonyi G., Seprodi A., Meszaros G., Szende B., Keri G. Activation of caspase-3 protease during the process of ursolic acid and its derivative-induced apoptosis. Anticancer Res. 2001, 21:3485-3491.
183. Hollosy F., Meszaros G., Bokonyi G., Idei M., Seprodi A., Szende B., Keri G. Cytostatic, cytotoxic and protein tyrosine kinase inhibitory activity of ursolic acid in A431 human tumor cells. Anticancer Res. 2000, 20:4563-4570.
184. Shishodia S., Majumdar S., Banerjee S., Aggarwal B.B. Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res. 2003, 63:4375-4383.
185. Shanmugam M.K., Rajendran P., Li F., Nema T., Vali S., Abbasi T., Kapoor S., Sharma A., Kumar A.P., Ho P.C., Hui K.M., Sethi G. Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice. J. Mol. Med. (Berl) 2011, 89:713-727.
186. Shanmugam M.K., Manu K.A., Ong T.H., Ramachandran L., Surana R., Bist P., Lim L.H., Kumar A.P., Hui K.M., Sethi G. Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model. Int. J. Cancer 2011, 129:1552-1563.
187. Pathak A.K., Bhutani M., Nair A.S., Ahn K.S., Chakraborty A., Kadara H., Guha S., Sethi G., Aggarwal B.B. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol. Cancer Res. 2007, 5:943-955.
188. Subbaramaiah K., Michaluart P., Sporn M.B., Dannenberg A.J. Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer Res. 2000, 60:2399-2404.
189. Honda T., Gribble G.W., Suh N., Finlay H.J., Rounds B.V., Bore L., Favaloro F.G., Wang Y., Sporn M.B. Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem. 2000, 43:1866-1877.
190. Yim E.K., Lee M.J., Lee K.H., Um S.J., Park J.S. Antiproliferative and antiviral mechanisms of ursolic acid and dexamethasone in cervical carcinoma cell lines. Int. J. Gynecol. Cancer 2006, 16:2023-2031.
191. Suh N., Wang Y., Honda T., Gribble G.W., Dmitrovsky E., Hickey W.F., Maue R.A., Place A.E., Porter D.M., Spinella M.J., Williams C.R., Wu G., Dannenberg A.J., Flanders K.C., Letterio J.J., Mangelsdorf D.J., Nathan C.F., Nguyen L., Porter W.W., Ren R.F., Roberts A.B., Roche N.S., Subbaramaiah K., Sporn M.B. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res. 1999, 59:336-341.
192. Hyer M.L., Croxton R., Krajewska M., Krajewski S., Kress C.L., Lu M., Suh N., Sporn M.B., Cryns V.L., Zapata J.M., Reed J.C. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 2005, 65:4799-4808.
193. Liby K., Hock T., Yore M.M., Suh N., Place A.E., Risingsong R., Williams C.R., Royce D.B., Honda T., Honda Y., Gribble G.W., Hill-Kapturczak N., Agarwal A., Sporn M.B. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005, 65:4789-4798.
194. Tanaka Y., Aleksunes L.M., Goedken M.J., Chen C., Reisman S.A., Manautou J.E., Klaassen C.D. Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity. Toxicol. Appl. Pharmacol. 2008, 231:364-373.
195. Liby K., Voong N., Williams C.R., Risingsong R., Royce D.B., Honda T., Gribble G.W., Sporn M.B., Letterio J.J. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin. Cancer Res. 2006, 12:4288-4293.
196. Liby K., Risingsong R., Royce D.B., Williams C.R., Yore M.M., Honda T., Gribble G.W., Lamph W.W., Vannini N., Sogno I., Albini A., Sporn M.B. Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268. Clin. Cancer Res. 2008, 14:4556-4563.
197. Pitha-Rowe I., Liby K., Royce D., Sporn M. Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN. Invest. Ophthalmol. Vis. Sci. 2009, 50:5339-5347.
198. Deeb D., Gao X., Dulchavsky S.A., Gautam S.C. CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells. Anticancer Res. 2007, 27:3035-3044.
199. Deeb D., Gao X., Jiang H., Dulchavsky S.A., Gautam S.C. Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR. Prostate 2009, 69:851-860.
200. Yore M.M., Kettenbach A.N., Sporn M.B., Gerber S.A., Liby K.T. Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. PLoS ONE 2011, 6:e22862.
201. Gao X., Deeb D., Liu P., Liu Y., Arbab-Ali S., Dulchavsky S.A., Gautam S.C. Role of reactive oxygen species (ROS) in CDDO-Me-mediated growth inhibition and apoptosis in colorectal cancer cells. J. Exp. Ther. Oncol. 2011, 9:119-127.
202. Zou W., Yue P., Khuri F.R., Sun S.Y. Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer Res. 2008, 68:7484-7492.
203. Vene R., Larghero P., Arena G., Sporn M.B., Albini A., Tosetti F. Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids. Cancer Res. 2008, 68:6987-6996.
204. Zou W., Chen S., Liu X., Yue P., Sporn M.B., Khuri F.R., Sun S.Y. C-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells. Cancer Biol. Ther. 2007, 6:1614-1620.
205. Vannini N., Lorusso G., Cammarota R., Barberis M., Noonan D.M., Sporn M.B., Albini A. The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. Mol. Cancer Ther. 2007, 6:3139-3146.
206. Samudio I., Kurinna S., Ruvolo P., Korchin B., Kantarjian H., Beran M., Dunner K., Kondo S., Andreeff M., Konopleva M. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol. Cancer Ther. 2008, 7:1130-1139.
207. Hyer M.L., Shi R., Krajewska M., Meyer C., Lebedeva I.V., Fisher P.B., Reed J.C. Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer. Cancer Res. 2008, 68:2927-2933.
208. Alabran J.L., Cheuk A., Liby K., Sporn M., Khan J., Letterio J., Leskov K.S. Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO. Cancer Biol. Ther. 2008, 7:709-717.
209. Liby K.T., Royce D.B., Risingsong R., Williams C.R., Maitra A., Hruban R.H., Sporn M.B. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev. Res. (Phila) 2010, 3:1427-1434.
210. Gao X., Deeb D., Liu Y., Arbab A.S., Divine G.W., Dulchavsky S.A., Gautam S.C. Prevention of Prostate Cancer with Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer. Cancers (Basel) 2011, 3:3353-3369.
211. Deeb D., Gao X., Liu Y., Jiang D., Divine G.W., Arbab A.S., Dulchavsky S.A., Gautam S.C. Synthetic triterpenoid CDDO prevents the progression and metastasis of prostate cancer in TRAMP mice by inhibiting survival signaling. Carcinogenesis 2011, 32:757-764.
212. E.H. Kim, C. Deng, M.B. Sporn, D.B. Royce, R. Risingsong, C.R. Williams, K.T. Liby, CDDO-methyl ester delays breast cancer development in brca1-mutated mice, Cancer Prev. Res., 2011.
213. Auletta J.J., Alabran J.L., Kim B.G., Meyer C.J., Letterio J.J. The synthetic triterpenoid, CDDO-Me, modulates the proinflammatory response to in vivo lipopolysaccharide challenge. J. Interferon Cytokine Res. 2010, 30:497-508.
214. Jutooru I., Chadalapaka G., Abdelrahim M., Basha M.R., Samudio I., Konopleva M., Andreeff M., Safe S. Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol. Pharmacol. 2010, 78:226-236.
215. Kim E.H., Deng C.X., Sporn M.B., Liby K.T. CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells. Cancer Prev. Res. 2011, 4:425-434.
216. Petronelli A., Pelosi E., Santoro S., Saulle E., Cerio A.M., Mariani G., Labbaye C., Testa U. CDDO-Im is a stimulator of megakaryocytic differentiation. Leuk. Res. 2011, 35:534-544.
217. Elsawa S.F., Novak A.J., Grote D., Konopleva M., Andreeff M., Witzig T.E., Ansell S.M. CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenstrom macroglobulinemia. Leuk. Res. 2008, 32:1895-1902.
218. Townson J.L., Macdonald I.C., Liby K.T., Mackenzie L., Dales D.W., Hedley B.D., Foster P.J., Sporn M.B., Chambers A.F. The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis. Clin. Exp. Metastasis 2011, 28:309-317.
219. Gao X., Deeb D., Hao J., Liu Y., Arbab A.S., Dulchavsky S.A., Gautam S.C. Synthetic triterpenoids inhibit growth, induce apoptosis and suppress pro-survival Akt, mTOR and NF-{kappa}B signaling proteins in colorectal cancer cells. Anticancer Res. 2010, 30:785-792.
220. Subba Rao G.S., Kondaiah P., Singh S.K., Ravanan P., Sporn M.B. Chemical modifications of natural triterpenes - glycyrrhetinic and boswellic acids: evaluation of their biological activity. Tetrahedron 2008, 64:11541-11548.
221. Kazakova O.B., Giniyatullina G.V., Yamansarov E.Y., Tolstikov G.A. Betulin and ursolic acid synthetic derivatives as inhibitors of Papilloma virus. Bioorg. Med. Chem. Lett. 2010, 20:4088-4090.
222. Wang P., Li C., Zang J., Song N., Zhang X., Li Y. Synthesis of two bidesmosidic ursolic acid saponins bearing a 2,3-branched trisaccharide residue. Carbohydr. Res. 2005, 340:2086-2096.